Today: 14 May 2026

Applied Materials stock slips as China’s 50% domestic chip-tool rule puts AMAT in the spotlight

Applied Materials stock slips as China’s 50% domestic chip-tool rule puts AMAT in the spotlight

Applied Materials shares fell 1.1% to $260.27 Tuesday after Reuters reported China now requires chipmakers expanding capacity to source at least 50% of equipment domestically. The iShares Semiconductor ETF was little changed. Wells Fargo raised its price target on Applied Materials to $290 and maintained an Overweight rating. Lam Research and KLA shares also slipped about 1%.
30 December 2025
·····
Why Travere Therapeutics (TVTX) stock is down today as insider sales hit the tape ahead of a key FDA date

Why Travere Therapeutics (TVTX) stock is down today as insider sales hit the tape ahead of a key FDA date

Travere Therapeutics shares fell 3.8% to $37.39 Tuesday afternoon, outpacing declines in biotech ETFs. SEC filings showed Chief Medical Officer Jula Inrig and Chief Commercial Officer Pieter Heerma sold shares on Dec. 24 under pre-arranged 10b5-1 plans. The moves come weeks before a key FDA decision on Filspari for FSGS, set for Jan. 13, 2026. Trading volume reached about 893,000 shares.
30 December 2025
Catalyst Pharmaceuticals stock drops 3% today as CPRX lags biotech in thin year-end trade

Catalyst Pharmaceuticals stock drops 3% today as CPRX lags biotech in thin year-end trade

Catalyst Pharmaceuticals shares fell 3% to $23.33 in thin afternoon trading Tuesday, extending a two-day slide and leaving the stock about 12% below its June high. Biotech ETFs underperformed the broader market, with the iShares Nasdaq Biotechnology ETF down 1.2%. Investors are awaiting the Federal Reserve’s meeting minutes and Catalyst’s next update in January.
30 December 2025
··
Kymera Therapeutics (KYMR) stock falls today as biotech slips — what traders are watching

Kymera Therapeutics (KYMR) stock falls today as biotech slips — what traders are watching

Kymera Therapeutics shares fell 3% to $77.94 Tuesday afternoon, underperforming a 1.4% drop in the SPDR S&P Biotech ETF. The decline follows December’s $692 million equity raise and positive Phase 1b data for its STAT6 degrader KT-621. The stock traded about 9% below its recent $86 offering price. Investors are watching for updates on trial progress and cash burn ahead of 2026 milestones.
30 December 2025
··
Almonty Industries stock today: ALM slips as CBS report spotlights U.S. tungsten supply deal

Almonty Industries stock today: ALM slips as CBS report spotlights U.S. tungsten supply deal

Almonty Industries shares fell 3.9% to $8.90 Tuesday after early gains, trading between $8.90 and $9.39. The drop followed news that CEO Lewis Black met U.S. officials and signed a deal tied to future tungsten supply from the Sangdong mine in South Korea, which is set to start production in early 2026. Almonty recently raised $129.4 million in a U.S. share sale and delivered its first ore to Sangdong’s staging area.
30 December 2025
···
Why Praxis Precision Medicines (PRAX) stock is down today after FDA breakthrough nod for its tremor drug

Why Praxis Precision Medicines (PRAX) stock is down today after FDA breakthrough nod for its tremor drug

Praxis Precision Medicines shares fell 3% to $295.50 Tuesday afternoon, retreating after a 14% surge Monday on FDA Breakthrough Therapy Designation for ulixacaltamide in essential tremor. The company plans to submit a New Drug Application in early 2026. Jefferies and BTIG raised price targets following the FDA news.
30 December 2025
··
Why Western Digital stock is down today: WDC slides as year-end rotation cools AI-hardware trades

Why Western Digital stock is down today: WDC slides as year-end rotation cools AI-hardware trades

Western Digital shares fell 1.7% to $176.55 Tuesday, reversing early gains and underperforming storage peers in thin year-end trading. The stock, up 303% in 2025, has been volatile amid portfolio reshuffling and investor focus on Fed policy signals. No company news was tied to the drop. Broader U.S. indexes were little changed.
30 December 2025
···
Why Caris Life Sciences (CAI) stock is down today as biotech slips

Why Caris Life Sciences (CAI) stock is down today as biotech slips

Caris Life Sciences shares fell 1.8% to $27.44 by 2:41 p.m. ET Tuesday, underperforming biotech peers as sector benchmarks declined. The drop followed recent attention on Caris’ Genentech partnership, which includes $25 million upfront and up to $1.1 billion in potential milestones. The S&P 500 and Nasdaq were flat. Investors are watching Caris’ test volumes and revenue guidance.
30 December 2025
Lululemon stock slips today as founder Chip Wilson launches proxy fight over board shake-up

Lululemon stock slips today as founder Chip Wilson launches proxy fight over board shake-up

Lululemon shares slipped 0.6% to $211.30 after founder Chip Wilson launched a proxy fight for board seats. The board said it will review Wilson’s nominees and issue a recommendation before the 2026 annual meeting. The move follows CEO Calvin McDonald’s decision to step down Jan. 31, with two executives named interim co-CEOs. Wilson holds a 4.27% stake and is acting alone, according to Reuters.
30 December 2025
·
Texas Instruments stock today: TXN flat after ReRAM licensing deal as Fed minutes land

Texas Instruments stock today: TXN flat after ReRAM licensing deal as Fed minutes land

Texas Instruments shares hovered near $176 after Weebit Nano licensed its ReRAM memory technology to the chipmaker for embedded processing chips. The stock slipped 0.01% to $175.67 in afternoon trading. The deal covers IP licensing and technology transfer, with Weebit’s ReRAM qualified for automotive-grade reliability. Trading volume was muted as investors digested the Fed’s latest meeting minutes.
30 December 2025
··
1 … 953 954 955 956 957 … 1,932

Stock Market Today

  • ABNB and BKNG Outperform Hyatt Hotels in Valuation and Growth Metrics
    May 14, 2026, 4:13 AM EDT. In the Hotels, Resorts & Cruise Lines industry, Airbnb (ABNB) and Booking Holdings (BKNG) show lower valuation and higher revenue and operating income growth compared to Hyatt Hotels (H). ABNB and BKNG trade at price-to-operating-income ratios (P/OpInc) of 30.7x and 12.9x respectively, versus Hyatt's 32.7x, while delivering stronger latest twelve months (LTM) and three-year average growth. Hyatt's LTM operating income growth stands at -0.4%, lagging ABNB's 4.1% and BKNG's 21.3%. Market capitalizations also differ notably, with Hyatt at $15.8 billion, ABNB at $79.5 billion, and BKNG at $122.5 billion. Despite strong growth elsewhere, Hyatt's higher valuation and weaker recent income growth suggest investors may favor ABNB and BKNG stocks. Multi-factor analysis remains essential before investment decisions.

Latest articles

Nvidia’s China H200 Chip Door Just Opened. The Money Still Isn’t Moving

Nvidia’s China H200 Chip Door Just Opened. The Money Still Isn’t Moving

14 May 2026
The U.S. has approved Nvidia to sell H200 AI chips to about 10 Chinese firms, including Alibaba and Tencent, but no shipments have occurred as Chinese buyers hold back under Beijing’s guidance. Nvidia CEO Jensen Huang is in Beijing with President Trump’s delegation ahead of the company’s May 20 earnings report. Lenovo confirmed it is cleared to distribute the chips in China.
Nokia Stock Surges Again as Cisco’s AI Orders Put New Heat Under the Network Trade

Nokia Stock Surges Again as Cisco’s AI Orders Put New Heat Under the Network Trade

14 May 2026
Nokia shares jumped about 10% in Helsinki Thursday, extending gains after Cisco reported $5.3 billion in AI infrastructure orders and raised its full-year outlook. Nokia launched new agentic AI tools for broadband networks and named Siemens executive Emma Falck as president of Mobile Infrastructure. The stock approached levels last seen 16 years ago.
Wall Street Feels the Heat (and Thrill): Fed Cuts, Tariffs & Mega-Mergers Set NYSE Buzz

US Stock Market Today: Live Updates 14.05.2026

14 May 2026
LIVEMarkets rolling coverageStarted: May 14, 2026, 12:00 AM EDTUpdated: May 14, 2026, 4:21 AM EDT ABNB and BKNG Outperform Hyatt Hotels in Valuation and Growth Metrics May 14, 2026, 4:13 AM EDT. In the Hotels, Resorts & Cruise Lines industry, Airbnb (ABNB) and Booking Holdings (BKNG) show **lower valuation** and **higher revenue and operating income growth** compared to Hyatt Hotels (H). ABNB and BKNG trade at price-to-operating-income ratios (P/OpInc) of 30.7x and 12.9x respectively, versus Hyatt's 32.7x, while delivering stronger latest twelve months (LTM) and three-year average growth. Hyatt's LTM operating income growth stands at -0.4%, lagging ABNB's 4.1% and
Go toTop